The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Got to be a typo surely! If not worst placing I may have ever seen
I would've thought the full 100% would be essential. You don't want good top-line results in q4, then submit the thing to the FDA with 75 patients for them to come back next year and say 'we can't pass this as you haven't given us the 80 patients we asked for'. As the CEO of a rotten share said last year before fda submission, "you only get one shot at this", so probably not a good idea to cut corners.
Seems to be a steady 10K seller, probably picked them up for 13p.
The Wall Street Journal reported on Jan 18th that the Fda have only been able to keep going in approving new drugs due to user fees from pharma cos. It says those fees will run out on Feb 8, but I saw that FDA group tweet about being ok to Feb 17 and possibly Feb 28. Can’t imagine pharma allowing the situation to drag on. Merck have a keytruda decision day on Feb 16, for instance.
I doubt the quietly-spoken GL has ever shouted from a hill top.
The US patents which provide exclusivity until 2037 surely add plenty of value when considering a buyout.
Nice to see long term hold in blue and not red any more, been a while.
Well 3m shares over two trades is 1% of the company, so if anyone over 3% it would break a threshold and require a tr1. Last year we had an update on January 18th so hopefully not long to wait til rev figures etc, be surprised if less than $7m.
No. Still below 40p by January 15, next Tues. Then Up to 50p and then a pull back to circa 42p as folk take some risk off the table. Risk almost nil, I know. Hoping partner news/licensing deal etc comes very soon after approval. Gla.
Either way, sub 30 to buy again
It’s nuts. I thought it was something to do with it being a SETS stock, which is usually used for bigger companies, but that may be a red herring. Sure other Aim shares use SETS too. It’s irritating how quickly a lid is put on any rise. After revive2 it went from 36p to 50p on open, but even by mid afternoon that day we were back to 45p. Makes me ponder what the best course of action is on Feb 13 all being well.
In Sept RRE had total cash of $95m. That figure is now $121m. Super.
Can approval come before Feb 13? The volume cant be due to just a MoS article?
Only two things I can think of is a) Austin’s tenure at IGas has made folk wary b) not as much oil hedged at 68 as previously thought. RRE’s numbers/cash look great, decom costs well under control, nice spread of oil/gas, pe of 1. Like others not sure what I’m missing here.
... bought a chunk at 540.
Why hasn’t the shares in issue been updated on this site? 12m, mcap circa £70m. PE of 1. Nuts.